Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06412315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

7T Amygdala and Citalopram Study

Study acronym: 7T FACES
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Oct 31, 2026 → Apr 30, 2027
See other at-risk trials from University of Oxford

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 31, 2026 to Apr 30, 2027
    • Enrollment target: 50 to 54
    • Eligibility criteria expanded, about 21 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Oct 31, 2025 to Oct 31, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2025 to Feb 13, 2025
    v3
  3. Start date: Jul 2024 to Feb 2025v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Oxford
180 trials monitored
See 6 trials at risk
Depression
3,055 trials monitored
See 173 trials at risk
The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds to emotional information. Healthy participants will undergo medical and psychiatric health screening, after which they will be assigned to receive either a single dose of citalopram (20mg) or placebo, and undergo brain scanning (7T fMRI) whilst viewing emotional faces. Since the scan uses high field strength, the investigators will be able to see effects of citalopram on different subfields within the amygdala which will help to understand how citalopram might be working.
Trial Details
NCT Number NCT06412315
Lead Sponsor University of Oxford
Conditions
(from sponsor)		 Emotional Processing, Cognition, Mood Disorders, Depressive Disorder, Depression
Related terms Depression, Depressive Disorder, Mood Disorders
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov